Staphylococcus vaccine

Staphylococcus vaccine (Staphypan) has been proposed as an immunomodulatory therapy in the treatment of Chronic Fatigue Syndrome. It was first used in Sweden with patients who became ill after a 1957 outbreak of Asian flu.

A Swedish study found significant improvement in Fibromyalgia and Chronic Fatigue Syndrome patients with a mean reduction in CPRS-15 scores of 50%.

A second study found significantly increased capacity of serum to neutralise alpha-toxin and a significant increase in serum IgG to alpha-toxin and lipase in patients receiving Staphypan.

Staphypan is no longer being commercially manufactured.

Staphylococcal vaccine favors Th1 dominance.